Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – Should You Buy?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) gapped up before the market opened on Wednesday . The stock had previously closed at $21.05, but opened at $21.8999. Chugai Pharmaceutical shares last traded at $21.0450, with a volume of 34,887 shares.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Nomura upgraded Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Finally, UBS Group downgraded shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, Chugai Pharmaceutical presently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Down 0.4%

The stock has a market cap of $69.00 billion, a PE ratio of 22.79 and a beta of 0.59. The firm has a 50-day simple moving average of $22.02 and a 200-day simple moving average of $24.99.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. The firm had revenue of $2.14 billion during the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. On average, research analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.